Literature DB >> 13896890

Antitumor efficacy of prednisone and sodium liothyronine in advanced breast cancer.

B GARDNER, A N THOMAS, G S GORDAN.   

Abstract

Entities:  

Keywords:  BREAST NEOPLASMS/therapy; PREDNISONE/therapy; TRIIODOTHYRONINE/therapy

Mesh：

Substances：

Year:  1962        PMID： 13896890     DOI： 10.1002/1097-0142(196203/04)15:2<334::aid-cncr2820150216>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  7 in total

1.  Corticosteroids in Therapy of Advanced Mammary Cancer.

Authors:  B A Stoll
Journal:  Br Med J       Date:  1963-07-27

Review 2.  Current status of the management of patients with endocrine-sensitive tumors. I. Introduction and carcinoma of the breast.

Authors:  L G Crowley
Journal:  Calif Med       Date:  1969-01

3.  Thyroid status and breast cancer. Reappraisal of an old relationship.

Authors:  A R Moossa; D A Evans; A C Brewer
Journal:  Ann R Coll Surg Engl       Date:  1973-09       Impact factor: 1.891

4.  Hormonal treatment of disseminated cancer of the female breast.

Authors:  G S GORDAN; W P GRAHAM; L GOLDMAN; R PAPAC; G E SHELINE; J VAETH; J WITT
Journal:  Calif Med       Date:  1963-04

Review 5.  Thyroid disease in relation to breast cancer.

Authors:  H Vorherr
Journal:  Klin Wochenschr       Date:  1978-12-01

6.  THYROID HORMONE AS A PROPHYLACTIC AGENT FOLLOWING RADICAL TREATMENT OF BREAST CANCER.

Authors:  A R LYONS; G A EDELSTYN
Journal:  Br J Cancer       Date:  1965-03       Impact factor: 7.640

7.  Plasma 3,3',5-Triiodo-L-thyronine [T3] level mirrors changes in tumor markers in two cases of metastatic cancer of the breast and pancreas treated with exogenous L-T3.

Authors:  Alejandro Rodríguez-Molinero; Aleck Hercbergs; Manuel Sarrias; Antonio Yuste
Journal:  Cancer Biomark       Date:  2018-02-06       Impact factor: 4.388
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.